View the full post GHTA launches free prostate cancer screenings on NOW Grenada.

View the full post Grenada shines at Caribbean Association of Pharmacists Conference on NOW Grenada.

View the full post Nexa Credit Union launches Healthier Nation Initiative on NOW Grenada.

Presidential candidate for A Partnership for National Unity (APNU), Aubrey Norton on Sunday assured residents of Linden that the electricity subsidy would not be scrapped. “We saying to you that wouldn’t happen under us. We want to see Linden progress,” he told about 2,000 attendees at a campaign rally held outside the old Palm Tree ...

Today we talk about an advance in an experimental mRNA vaccine for HIV, dive deep on Vinay Prasad’s sudden FDA departure, and more.

The need-to-know this morning

• Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.
• Biogen, Argenx, Sanofi, and Bristol Myers Squibb reported second-quarter earnings. 
• AbbVie and Apellis Pharma reported earnings, too. 

Inside the undoing of Vinay Prasad at the FDA

Vinay Prasad’s short-lived but polarizing run as head of the FDA’s biologics division ended just 84 days in, after his aggressive push to tighten oversight on gene therapies and Covid-19 vaccines drew heat from all sides — Trump allies, RFK Jr. loyalists, Democrats, and Duchenne patient advocates.

His decision-making on Sarepta Therapeutics’ gene therapy— which he viewed as backed by staff and rooted in safety concerns — fueled political pressure that only mounted after far-right influencer Laura Loomer launched a campaign highlighting his progressive leanings and past anti-Trump comments. A powerful and extremely online regulator ran out of friends when it mattered most.

Continue to STAT+ to read the full story…

View the full post Sandals Resorts awarded CARPHA’s highest health and safety honour on NOW Grenada.

Bids must be submitted electronically only through the e-procurement portal on or before 5 September 2025 no later than 2 pm

View the full post Request for Bids: Upgrade works at St David’s Health Centre on NOW Grenada.

Guyana has acquired Merck-made 9-valiant HPV (human papilloma virus) vaccines at a very low cost through a deal negotiated by the Pan-American Health Organisation (PAHO), according to Health Minister Dr Frank Anthony. The HPV virus is responsible for most cervical cancers. The virus can also cause anal, penile, vulvar, vaginal, and some head and neck ...

The Guyana Defence Force (GDF) has shifted gears into the use of aerospace defence systems to protect the country, President Irfaan Ali announced at the commissioning ceremony for a new Italian-made utility plane. “We have expanded our air assets and capability to include our aerospace investment,” he told the event to officially welcome the Tecnam ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello! Today, we talk about a cool experimental enzyme therapy, observe more patent maneuvers over Eylea, and see an ‘underdog’ startup get a huge seed round to target a common kidney disease.

The need-to-know this morning

• Soleno Therapeutics pre-announced $31-33 million in Vykat XR sales for the second quarter — beating consensus expectations by a wide margin. The drug was approved in late March to treat Prader-Willi syndrome, a rare genetic disease that causes an insatiable desire to eat. Soleno is also raising $200 million in a follow-on stock sale.
• AbbVie is paying $700 million upfront to acquire licensing rights to a “trispecific antibody” treatment for cancer developed by Ichnos Global Innovation. The drug, called ISB 2001, targets CD38 and BCMA protein receptors on tumor cells and the CD3 receptor on T cells. A Phase 1 study in multiple myeloma is underway.

Brawl over Eylea gets biosimilar industry’s attention

A high-stakes legal fight between Regeneron and Amgen over the blockbuster eye drug Eylea is putting the U.S. patent system under a microscope — and is being closely watched by biosimilar makers.

Continue to STAT+ to read the full story…